Skip to content
Company Analysis

ResMed Inc. RMD

A comprehensive view of key metrics, scores, and financial health for ResMed Inc.

Overview of ResMed Inc.

RMD NYQ
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Large Cap
ResMed Inc. (RMD), is a Large Cap company, in the Medical Instruments & Supplies industry, last closed at $221.05, about 65.7% overvalued vs fair value, -18.2% 1Y return, placing in the top 10% of its sector.
Metrics Gross Margin 61.1%
USD 221.05
-3.20%
(Delayed)
• Vol 90d: 37.0%
52-Week Range
Market Cap
$30.07B
Enterprise Value
$29.42B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Good
Growth
Good
Profitability
Excellent
Health
Fair
Efficiency
Good
Valuation
Good
Completeness: 100%
Confidence: 62%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.resmed.com
HQ San Diego, CA
Fiscal year Jun 30

Next Events

Dividend Sep 24
Earnings Oct 29 Estimated

Fair Value Snapshot

Bear Base Bull
$68
$76
$84
Current: $221.05 -66% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$5.7B
9.9%%
Gross Profit
$3.5B
13%%
Operating Income (GAAP)
$1.9B
13.2%%
EBITDA
$2.2B
12%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
61.1%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$1.0B
64.5% of Free Cash Flow

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating ResMed Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
83
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Superior Capital Returns Capital return quality is top-tier (score 0.96). High ROIC indicates the business is reinvesting at attractive rates.
  • Strong FCF Generation FCF margin quality is top-tier vs peers (score 0.98). High FCF conversion confirms strong earnings quality.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
70
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing RMD's balance between Growth (25.7%), Profitability (39.5%), and Safety (34.8%). Growth 26% Safety 35% Profitability 40%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

57th percentile vs peers
58
Key Signals
Rev Growth YoY 9.8% 58p Revenue CAGR 3Y 12.9% 63p EPS CAGR 3Y 28.8% 72p EPS Growth YoY 13.7% 41p TSR -9.9% 42p
Strengths
  • FCF Margin in top 20% of peers (32.1%, 98th percentile)
  • Operating Margin in top 20% of peers (32.8%, 99th percentile)
  • ROIC in top 20% of peers (21.1%, 94th percentile)
  • Interest Coverage (EBITDA) in top 20% of peers (152.53, 96th percentile)
Risks

No significant risks identified for this axis.

Profitability

88th percentile vs peers
89
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

78th percentile vs peers
78
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for ResMed Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$75.75
- - -
-65.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000